Bausch Health Companies | VRX - Interest Expense On Debt


Bausch Health Companies reported $397M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Amgen USD 657M 4M Mar/2026
ANI Pharmaceuticals USD 4.41M 316K Dec/2025
Aurora Cannabis CAD 230K 1.88M Mar/2026
Bausch Health Companies USD 397M 15M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Canopy Growth CAD 12.31M 4.97M Mar/2026
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Danaher USD 63M 8M Mar/2026
Drreddys Laboratories INR 1.06B 113M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Pacira USD 3.7M 193K Mar/2026
Perrigo USD 7.98B 7.94B Mar/2026
Phibro Animal Health USD 11.91M 191K Dec/2025
Prestige Brands USD 10.67M 636K Dec/2025
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zoetis USD 62M 5M Mar/2026